1st Quarter - Report

SEQIRUS for SEQIRUS

Period 1st Quarter 2025 Filed Apr 21, 2025 Signed by James Sherner

Official filing
Firm
SEQIRUS
Client
SEQIRUS
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY2025 Appropriations, policies related to pandemic preparedness and public health; HR 5846, Protecting America from Seasonal and Pandemic Influenza Act of2023; S 3219, Influenza Act; FY2025 NDAA, issues related to influenza surveillance and vaccine development; Pandemic and All-Hazards Preparedness Reauthorization.

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

LobbyistCovered position, as disclosed
CHRISTINE FARQUHARSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Security Council (NSC)

Bills named: H.R. 5846 (119th)

Health Issues HCR

FY2025 Appropriations, policies related to pandemic preparedness and public health; HR 5846, Protecting America from Seasonal and Pandemic Influenza Act of2023; S 3219, Influenza Act; FY2025 NDAA, issues related to influenza surveillance and vaccine development; Pandemic and All-Hazards Preparedness Reauthorization.

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

LobbyistCovered position, as disclosed
CHRISTINE FARQUHARSON —

Contacted: Natl Security Council (NSC); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5846 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.